Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B7NG
|
|||
Former ID |
DAP000336
|
|||
Drug Name |
Chlorpheniramine
|
|||
Synonyms |
Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Allergic rhinitis [ICD-11: CA08.0] | Approved | [1], [2] | |
Therapeutic Class |
Antiallergic Agents
|
|||
Company |
Schering-Plough Corporation
|
|||
Structure |
Download2D MOL |
|||
Formula |
C16H19ClN2
|
|||
Canonical SMILES |
CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
|
|||
InChI |
1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
|
|||
InChIKey |
SOYKEARSMXGVTM-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 113-92-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9299815, 11110931, 11110932, 11112256, 11363014, 11365576, 11368138, 11371329, 11373943, 11376300, 11484028, 11487972, 11490161, 11492097, 11493954, 15442268, 33774101, 47719847, 48018097, 50064683, 50100400, 50225325, 57304992, 85789162, 109896795, 135650086, 135774423, 137002507, 160666558, 174007153, 175269603, 179039539, 226396260
|
|||
ChEBI ID |
CHEBI:52010
|
|||
ADReCS Drug ID | BADD_D00444 ; BADD_D02400 | |||
SuperDrug ATC ID |
R06AB04
|
|||
SuperDrug CAS ID |
cas=000132229
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Akkermansia muciniphila was decreased by Chlorpheniramine maleate (adjusted p-values: 3.22E-03). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [4], [5], [6] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Inflammatory mediator regulation of TRP channels | ||||
Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
Reactome | Histamine receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
IL-4 Signaling Pathway | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6976). | |||
REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070797. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. | |||
REF 5 | Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol. 1999 Sep-Oct;13(5):391-9. | |||
REF 6 | Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Jan 1;266(1):99-102. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.